Copyright © 2021. Inderes Oyj. All rights reserved.
Käyttäjätili

Hei!

Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.

Oliko sinulla jo tili?

Kirjaudu sisään

The following resolutions were passed at the annual general meeting (the “AGM”) of CellaVision AB (publ) (“CellaVision”) on 29 April 2021. Due to the covid-19 pandemic, CellaVision‘s annual general meeting was carried out through advance voting (postal voting) only.

Adoption of income statement and balance sheet and discharge from liability
The AGM resolved to adopt the income statement for the financial year 2020 as well as the balance sheet and consolidated balance sheet as of 31 December 2020. The members of the board of directors and the managing director were discharged from liability for the financial year 2020.

Allocation of profit or loss
The AGM resolved, in accordance with the Board of Directors’ proposal, on a dividend of SEK 0.75 per share, with record date 3 May 2021. The dividend is expected to be paid by Euroclear Sweden AB on
6 May 2021.

Board of Directors and auditor
The AGM resolved, in accordance with the nomination committee’s proposal, on re-election of Mikael Worning, Anna Malm Bernsten, Christer Fåhraeus, Åsa Hedin, Niklas Prager, Jürgen Riedl and Stefan Wolf as board members. Mikael Worning was also elected as the chairman of the Board of Directors. The AGM re-elected the audit firm Deloitte AB as auditor.

The AGM further resolved in accordance with the nomination committee’s proposal on remuneration to the Board of Directors, remuneration for committee work and that remuneration to the auditor shall be paid in accordance with approved statement of costs.

Nomination committee for the next annual general meeting
The AGM resolved, in accordance with the nomination committee’s proposal, that the same principles for appointing the nomination committee that were resolved upon at the AGM of 2020 shall also apply for the AGM of 2022.

Remuneration report
The AGM approved the Board of Directors’ remuneration report for 2020.

Amendment of the articles of association
The AGM resolved, in accordance with the Board of Directors’ proposal, to amend the articles of association.

CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China and Japan. The company derives the majority of its revenue from the sale of analyzers.